Matching articles for "finerenone"
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics • January 23, 2023; (Issue 1668)
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral...
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral nonsteroidal
mineralocorticoid receptor antagonist (MRA)
finerenone (Kerendia) to standard treatment in
patients with type 2 diabetes and chronic kidney
disease (CKD).
Finerenone (Kerendia) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • August 23, 2021; (Issue 1631)
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal...
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal disease,
nonfatal MI, hospitalization for heart failure (HF), and
cardiovascular death in adults with chronic kidney
disease (CKD) associated with type 2 diabetes. It is the
first nonsteroidal MRA to be approved in the US.